Pulmonary surveillance in inborn errors of immunity: current challenges and emerging approaches - Report - MDSpire

Pulmonary surveillance in inborn errors of immunity: current challenges and emerging approaches

  • By

  • Ernest Hoptioncann

  • Rachel L. Eddy

  • Catherine M. Biggs

  • Jonathan H. Rayment

  • May 20, 2026

  • 0 min

Share

Clinical Report: Monitoring Lung Health in Genetic Immune Disorders

Overview

Inborn errors of immunity (IEIs) significantly increase the risk of pulmonary complications, primarily due to recurrent infections and immune dysregulation. Emerging monitoring techniques, such as multiple-breath washout and pulmonary MRI, may enhance detection and management of these complications.

Background

Pulmonary complications are a leading cause of morbidity and mortality in individuals with inborn errors of immunity (pwIEIs). The high prevalence of these complications necessitates effective monitoring strategies to improve patient outcomes. Traditional methods have limitations, highlighting the need for innovative approaches to assess lung health in this vulnerable population.

Data Highlights

Complication TypePrevalence (%)
Airway Disease86.8
Parenchyma Involvement18.5
Pleura Involvement4.6
Vasculature Involvement4.3

Key Findings

  • Nearly 40% of pwIEIs develop pulmonary complications.
  • Common variable immunodeficiency (CVID) accounts for nearly half of all reported pulmonary complications.
  • Pulmonary complications contribute to 17.4% of deaths in pwIEIs.
  • Recurrent infections lead to chronic airway disease, notably bronchiectasis.
  • Emerging techniques like pulmonary MRI offer radiation-free assessments of lung function.

Clinical Implications

Healthcare providers should consider incorporating advanced monitoring techniques to better assess lung health in pwIEIs. A multidisciplinary approach is essential for managing pulmonary complications effectively, including regular pulmonary function testing and imaging.

Conclusion

The high burden of pulmonary complications in pwIEIs underscores the need for improved monitoring strategies. Utilizing emerging technologies may enhance patient care and outcomes in this population.

Related Resources & Content

  1. AAAAI/ACAAI/CIS, PubMed, 2026 -- 2025 Inborn errors of immunity practice parameter: Guidance from the Joint Task Force on Practice Parameters
  2. Frontiers, 2025 -- Granulomatous lymphocytic interstitial lung disease in common variable immune deficiency
  3. The ASCO Post — Managing Toxicities Associated With Immunotherapy for Lung Cancer
  4. The ASCO Post — Immunotherapy Challenges in Lung Cancer: From Patient Selection to Clinical and Financial Toxicity
  5. The ASCO Post — Combination Immunotherapy for Lung Cancer: The Wave of the Future
  6. The ASCO Post — Patients With Lung Cancer and a Genetic Variant Linked to Autoimmune Disease May Be Especially Responsive to Immunotherapy
  7. Managing Toxicities Associated With Immunotherapy for Lung Cancer
  8. Immunotherapy Challenges in Lung Cancer: From Patient Selection to Clinical and Financial Toxicity
  9. Combination Immunotherapy for Lung Cancer: The Wave of the Future
  10. 2025 Inborn errors of immunity practice parameter: Guidance from the Joint Task Force on Practice Parameters, the American Academy of Allergy, Asthma & Immunology (AAAAI), the American College of Allergy, Asthma and Immunology (ACAAI) and the Clinical Immunology Society (CIS) - PubMed
  11. Frontiers | Granulomatous lymphocytic interstitial lung disease in common variable immune deficiency: an in-depth clinical, immunological, functional and radiological exploration with a focus on its management, challenged by chronic CMV infection
  12. ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease | European Respiratory Society

Original Source(s)

Related Content